Recent evidence has established a compelling correlation between high serum sclerostin levels and postmenopausal osteoporosis-related fractures.132 As a potent suppressor of bone formation, sclerostin has become an attractive target in anabolic bone therapies. The gene discussed is SOST; the disease is postmenopausal osteoporosis.